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INTRODUCTION:
tRNAs read mRNA codons in translation and are essential for protein synthesis. Like mRNA, the concentration and the identity of tRNAs are also under stringent cellular control. Our project aims to determine whether tRNAs serve as biomarkers for breast cancer cells and whether tRNAs in normal and breast cancer cell lines control the expression of selected genes that are important for the tumorigenic process. Finding tRNA as biomarkers could open up a new and so far under-appreciated avenue for detecting the type and stage of breast cancer progression. Identification of tRNAs that regulate tumor development and progression could produce targets for a new class of cancer drugs.
BODY (Tables and Figures at the end of the text):
Task 1: Development of a "second-generation" tRNA microarray capable of studying single-nucleotide differences in human tRNA.  Completed when the last annual report was written in August 2008.
Task 2: Development of a "third-generation" method capable of studying the expression of >90% of human tRNA species.  In development.
After the successful development of the "second-generation" microarray method (task 1), we realized that the most effective way for completing task 2 is to apply the newly available, high throughput DNA sequencing method (e.g. Solexa technology by Illumina). This new technology offers a much higher data output at a significantly reduced cost. We are continuing to work on this.
Task 3:
Evaluate the usefulness of tRNA expression pattern as biomarkers  Completed.
To explore the potential of tRNAs to define breast cancer signatures, we used tRNA microarrays to generate comparative tRNA profiles for three non-tumorigenic breast epithelial cell lines (MCF10A, 184 A1, 184 B5) and six breast cancer cell lines (BT-474, HCC70, MCF7, MDA-MB-231, MDA-MB-436, ZR-75-1). The breast cancer cell lines cover a range of physiological and molecular properties (Table 1) . Importantly, genome-wide mRNA expression data are available for these cell lines (1) to allow tRNA expression and codon usage correlation analysis.
Significant differences are observed in the expression levels of tRNA among nontumorigenic and tumorigenic breast cell lines (Fig. 1A, 1C) . The global level of nuclear-and mitochondrial-encoded tRNAs can be approximated separately by the median and mean sample-to-MCF10A ratio. For nuclear-encoded tRNAs, this ratio is 0.7-0.8 for the other non-tumorigenic cell lines and 2-3 for the tumorigeniccell lines. These differences are even more pronounced for mitochondrial-encoded tRNA levels: the sample-to-MCF10A ratio for non-tumorigenic cell lines is approximately 0.75, but as much as 5 for the tumorigenic cells.
The over-expression of tRNA in tumorigenic relative to non-tumorigenic cell lines is also selective: certain individual tRNAs are more strongly over-expressed than others (Fig. 1C) . Variations in the relative expression of nuclear-encoded tRNAs carrying certain amino acid types are readily observed across tumorigenic cell lines. For example, nuclear-encoded tRNAs carrying polar amino acids (e.g. Ser, Thr, and Tyr) are up-regulated 3 to 4-fold in breast cancer cell lines relative to MCF10A, while nuclear-encoded tRNAs carrying small amino acids (Ala, Cys, Gly, Pro) are up-regulated only 1.5 to 2-fold. These differences can be observed more clearly when the tRNA expression is normalized to the median value for either nuclear-or mitochondrial-encoded tRNAs within each cell line (Fig. 1C, 1D ). Differences in the relative expression of tRNA isoacceptors also become more apparent after normalization. Selective up-regulation of tRNA levels is also observed for mitochondrial-encoded tRNAs: certain tRNAs are expressed up to 2-fold above median, and others are expressed 4-fold below median. While nuclear-encoded tRNA expression patterns are remarkably similar across cell lines, mitochondrial-encoded tRNA expression patterns exhibit greater variations.
We also determined that tRNA over-expression in breast cancer cell lines does not simply reflect an increase in proliferation rate (Table 2) . Under the culture conditions used in this study, doubling times range from 21 to 47 hours for the non-tumorigenic cell lines, versus 15 to 35 hours for the tumorigenic cell lines. Thus, the proliferation of all three non-tumorigenic cell lines with low tRNA content is comparable to that of tumorigenic breast cancer cell lines with much higher tRNA content. Doubling times do not correlate with either nuclear or mitochondrial global tRNA levels (not shown).
tRNA over-expression in patient-derived breast tumor samples: In all breast cancer cell lines examined, we observe global tRNA over-expression and differential tRNA isoacceptor expression. To generalize our results in cell lines to breast cancer in vivo, we measured tRNA expression patterns in 9 patient-derived breast tumor samples and 3 normal breast tissue samples ( Table 3 ). The 9 breast tumor samples were selected from the three major subtypes of breast cancer: luminals (ER+, HER2-), basals (ER-, HER2-), and HER2+. For consistency of data analysis, all samples were run using MCF10A as a reference in array experiments.
As in the breast cancer cell lines, we observe significant differences in global tRNA expression levels among breast tumor and normal breast samples ( Fig. 2A, 2B ). For nuclearencoded tRNAs, the mean sample-to-MCF10A ratios is 0.2 to 0.5 for normal breast tissue samples, compared to 2 to 4 for breast tumor samples. This translates to up to 20-fold upregulation of global nuclear-encoded tRNA levels in breast tumors relative to normal breast. For mitochondrial-encoded tRNAs, the mean sample-to-MCF10A ratio is 0.4 to 1 for normal breast tissue samples, compared to 1.2 to 5 for breast tumor samples. This translates to up to 13-fold upregulation of global mitochondrial-encoded tRNA levels in breast tumors relative to normal breast. Consistent with our results on cell lines, tRNA over-expresssion in breast tumor samples is also selective: certain individual tRNAs are more strongly over-expressed than others (Fig. 2C ). Among the top 10 over-expressed, nuclear-encoded tRNAs, six tRNA species overlap for cell lines and tumor tissues. We readily observe variations in the relative expression of both nuclear-and mitochondrial-encoded tRNAs. These variations correlate with both the cognate amino acid type and tRNA isoacceptor identity. We also observe variations in the relative expression of tRNA isoacceptors. These variations become more clear when tRNA expression levels are normalized to the median value within each sample (Fig. 2D) . However, tRNA expression pattern in the three major sub-types of breast cancer is very similar, suggesting that tRNA over-expression is a general consequence for all breast tumors.
We conclude that elevated tRNA levels are a hallmark of breast cancer. Our results suggest that tRNAs can be used as biomarkers for breast cancer, although it is best suitable to determine tumorigenic versus normal breast cells. Furthermore, tRNA expression measured by microarrays more accurately reflects the "functional abundance" of individual tRNA species.
Task 4:
Identify correlations between tRNA and mRNA expression:  Completed.
The differential expression of tRNA isoacceptors can be used to regulate translational efficiency via the codon usage of specific genes. In prokaryotes and fungi, differences in the abundance of tRNA isoacceptors are correlated with codon preferences of genes encoding highly expressed proteins and impact the synthesis of these proteins (2-4). In humans, tissue-specific differences in the expression of individual tRNA species can correlate to the codon usage of highlyexpressed, tissue-specific genes, although this correlation was seen only for a small number of tissues (5).
tRNA isoacceptor levels in breast cancer cell lines may also correlate with the codon usage of certain genes that are important for cancer. Finding such correlations would suggest an additional level of translational regulation for breast cancer cell lines, and by extension for breast cancer in vivo. At least three groups of genes are relevant in seeking codon usage-tRNA correlation for cancer cell lines: cell-line specific genes, cancer-related genes and house-keeping genes (Fig. 3A) . Cell-line specific genes can be important for distinct tumorigenic properties across cell lines; cancer-related genes can be important for general tumor initiation and progression; and housekeeping genes are important for cell growth and architecture.
To identify cell line-specific genes, we used the publicly available mRNA expression data for the breast cancer lines and MCF10A (http://www.ebi.ac.uk/arrayexpress/, accession number E-TABM-157). To identify cell line-specific genes, we used publicly available mRNA expression data ((http://www.ebi.ac.uk/arrayexpress/, accession number E-TABM-157). Cell line-specific genes were selected based on mRNA expression level (7-to 15-fold above the median expression level determined for all genes) and high cell line/MCF10A expression ratios (top 20 to 30 genes). A cell line-specific gene set was determined for each breast cancer cell line. To identify cancer-related genes, we selected from a comprehensive list of potential breast cancer diagnostic markers (http://www.sabiosciences.com/gene_array_product/HTML/OHS-402.html). Genes in this group are highly associated with breast cancer (6) . Functional groupings used in our study include: cell cycle, cell growth and proliferation, ECM molecules, protein kinases, and transcription factors/regulators. To identify house-keeping genes, we selected the 30 most highly expressed house-keeping genes as defined in a previous report (6) . This list includes ribosomal proteins, actin, ubiquitin, and others.
For each gene set, we compiled gene sequences and analyzed them for codon usage (expressed as number per one thousand codons, www.bioinformatics.org/sms2) ( Tables 4 and 5 ). Because certain tRNAs read more than one codon, we converted the obtained codon usage into tRNA-based codon usage. For example, tRNA Arg(ICG) reads both CGU and CGC. Its tRNA-based codon usage is therefore equal to the sum of the CGU and CGC codon usages. For simplicity, we refer to tRNA-based codon usage as codon usage throughout our analysis.
We first compared the codon usages of each gene set in the three gene groups (cell linespecific, cancer-related, and housekeeping) against each other (Fig. 3B) . Though there is limited overlap across cell line-specific gene sets, their codon usage was remarkably similar (average r s = 0.92 ± 0.04). The codon usage of cell-line specific gene sets also correlates with the codon usage of the housekeeping genes (average r s = 0.80 ± 0.08), but to a significantly lesser extent (p-value <0.01). Similarly, the codon usages of cancer-related gene sets correlate remarkably welll with each other (average r s = 0.92 ± 0.05) but to a lesser extent with the housekeeping genes (average r s = 0.83 ± 0.06, p-value <0.01). These results suggest functionally different gene groups have significantly different codon usages.
Is the codon usage of cell-line specific genes related to the over-expression patterns of nuclear-encoded tRNAs in breast cancer cells? We plotted relative isoacceptor levels (derived from comparative tRNA measurements) versus the codon frequency of cell-line specific genes (derived from comparative mRNA analysis) to determine whether the changes in tRNA levels favor the codon usage of these genes. No obvious correlations were observed (not shown). The absence of correlations may be explained by the low mRNA level of these genes at the global scale (Fig. 3A) . The cell line-specific genes identified for this study are expressed only 7-to 15-fold above the median expression level of all genes, compared to approximately 80-fold above median for the housekeeping genes. Among human tissues examined, a significant tRNA abundance-codon usage correlation was found only in liver (5) . The mRNA levels of liver-specific genes approach those of house-keeping genes (200-fold above median), sufficiently high for tRNAs to adjust to their respective codon usages. Because the codon usage of line-specific genes is different from that of house-keeping genes, adjusting tRNA levels to favor expression of cell line-specific genes would be unfavorable for translation of house-keeping genes.
The codon usage of cancer-related genes, however, appears to have some correlations to relative tRNA over-expression in cancer cell lines (Fig. 3C-E ). Since the tRNA over-expression pattern is similar for the nuclear-encoded tRNAs across all lines examined, we used the average tRNA over-expression for all 6 cancer lines for this analysis. Bearing in mind that tRNA overexpression cannot favor all codons of cancer-related genes because such tRNA adjustment would diminish the translational efficiency of house-keeping genes, we reasoned that a positive correlation should reveal itself only for codons that are strongly over-represented in cancer-related relative to house-keeping genes. A positive correlation between tRNA over-expression and codon usage is indeed observed for codons over-represented by 2-fold or more for the cell cycle, extracellular matrix, and transcription factor groups (Fig. 3C) . Among the group of 28 cell cycle genes ranked by their average mRNA expression levels in all lines, a similar correlation can be seen when comparing the codons that are over-represented in the 9 genes with the highest mRNA expression versus the 9 genes with the lowest mRNA expression (Fig. 3D) . Finally, tRNA
Arg isoacceptors seem to be particularly tuned to increase the translational efficiency of Arg-codons of the cell cycle, extracellular matrix and transcription factor genes (Fig. 3E ).
Task 5:
Identify correlations between tRNA and active protein synthesis:  In development.
Based on the results from Task 4, we have selected several gene targets for protein expression studies. We are still working on refining the methodology for this study.
KEY RESEARCH ACCOMPLISHMENTS:
-Determined the feasibility of using tRNA expression as possible biomarkers for breast cancer cell lines. -Determined the feasibility of using tRNA expression as possible biomarkers for tumor versus normal breast tissues. -Determined that tRNA expression has some correlation to optimal translation of breast cancer related genes.
REPORTABLE OUTCOMES:
-A revised manuscript is now under review in Nucleic Acids Research. Title: tRNA Overexpression in Breast Cancer and Functional Consequences. Authors: Mariana PavonEternod, Suzanna Gomes, Renaud Geslain, Qing Dai, Marsha Rich Rosner, Tao Pan.
CONCLUSION:
Our results show for the first time that tRNAs are good candidates as molecular biomarkers for breast cancer cells. This conclusion, initially established in breast cancer cell lines, has been firmly established in tumor and normal breast tissues. Both nuclear and mitochondrial-encoded tRNAs show distinct patterns in different breast cancer cells with varying tumorigenic characteristics.
Another important aspect of our tRNA study is to discover the possibility that altering tRNA expression in breast cancer may lead to changes in cellular behavior. We have found correlations between tRNA overexpression and the codon usage of breast cancer related genes. Altering this relationship may lead to the identification of certain tRNAs or their associated protein enzymes as potential new drug targets for breast cancer. Table 2 . Breast Cell Line Doubling Times Cell proliferation was measured over four days using the Promega CellTiter Blue metabolic assay. Cells were plated at low cell density (1,500 cells/well) and high cell density (5,000 cells/well). Doubling times were calculated from the equation: N/No = e(kt). Values are averages of three replicates. 
